返回 
加入收藏
地塞米松联合利妥昔单抗一线治疗成人慢性原发免疫性血小板减少症的经济性评价
x
请在关注微信后，向客服人员索取文件
| 篇名： | 地塞米松联合利妥昔单抗一线治疗成人慢性原发免疫性血小板减少症的经济性评价 |
| TITLE： | Economic Evaluation of Dexamethasone Combined with Rituximab for the First-line Treatment of Chronic Primary Immune Thrombocytopenia in Adults |
| 摘要： | 目的：评价地塞米松（DXM）联用利妥昔单抗（RTX）一线治疗成人慢性原发免疫性血小板减少症（ITP）的经济性。方法：从我国医疗卫生体系角度出发，以单用DXM方案为对照，构建八状态Markov模型，模型周期为4周，时限为20年，评价DXM联用RTX方案治疗成人慢性ITP的成本-效用，临床疗效、效用值参数来自已发表的文献，成本参数来自米内网、各地卫生健康委以及医保局官网；通过单因素敏感性分析、概率敏感性分析和情境分析来考察模型及参数来源的不确定性。结果：DXM+RTX方案的平均治疗费用为51064美元，DXM方案的平均治疗费用为50455美元；与单用DXM相比，DXM+RTX方案可以让每位患者平均多获得0.14个质量调整生命年（QALYs），增量成本-效果比（ICER）为4356美元/QALY，低于2020年我国人均国内生产总值（GDP）这一意愿支付阈值。在单因素敏感性分析中，药品费用是对结果影响最大的参数；在概率敏感性分析中，当支付阈值为1～3倍2020年我国人均GDP时，DXM+RTX方案具有经济性的概率为57.5％～61.0％；情境分析结果表明，DXM+RTX方案可能具有明显的长期获益，效用值对结论的影响较小。结论：DXM+RTX相比单用DXM一线治疗成人慢性ITP具有经济性，但是结果具有一定的不确定性。 |
| ABSTRACT： | OBJECTIVE：To evaluate the economy performance of dexamethasone （DXM）combined with rituximab （RTX） for the first-line treatment of chronic primary immune thrombocytopenia （ITP）in adults. METHODS ：From the perspective of China ’s medical and health system ，Markov model for eight states was constructed with a period of 4 weeks and a time limit of 20 years， using DXM regimen as control. The cost-utility of DXM+RTX regimen for the treatment of chronic ITP in adults were evaluated. The parameters of clinical efficacy and utility value were derived from own published literature ；cost parameters were from the MENET website and the official websites of local health committees and medical insurance bureaus ；one-way sensitivity analysis ， probability sensitivity analysis and scenario analysis were performed to observe the uncertainty of model and data source. RESULTS：The average cost of DXM+RTX regimen was 51 064 dollars and that of DXM regimen was 50 455 dollars. Compared with DXM regimen ，DXM+RTX regimen yielded an additional 0.14 QALYs for each patient ；the incremental cost-effectiveness ratio（ICER）was 4 356 dollars/QALY，and was lower than the willingness-to-pay threshold of China ’s per capita gross domestic product（GDP）in 2020. In the one-way sensitivity analysis ，the cost of drugs was the main driver in the model. Probability sensitivity analysis demonstrated that DXM+RTX regimen had 57.5％-61.0％ probability of being cost-effective at a willingness- to-pay threshold of 1-3 times per capita GDP in 2020. The results of scenario analysis showed that DXM+RTX regimen would have obvious long-term benefits ，and the utility value had little impact on the conclusion. CONCLUSIONS ：DXM + RTX is more economical than DXM in the treatment of chronic ITP in adults ，but the results have the uncertainty. |
| 期刊： | 2021年第32卷第24期 |
| 作者： | 王樱澄，芮明军，商叶，马爱霞 |
| AUTHORS： | WANG Yingcheng，RUI Mingjun，SHANG Ye，MA Aixia |
| 关键字： | 药物经济学评价；原发免疫性血小板减少症；利妥昔单抗；地塞米松；一线治疗 |
| KEYWORDS： | Pharmacoeconomic evaluation； Primary immune throm bocytopenia； Rituximab； Dexamethasone； First-line |
| 阅读数： | 275 次 |
| 本月下载数： | 3 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
